At the time of writing, Ideaya Biosciences Inc [IDYA] stock is trading at $30.20, up 2.44%. An important factor to consider is whether the stock is rising or falling in short-term value. The IDYA shares have gain 3.25% over the last week, with a monthly amount drifted -16.57%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ideaya Biosciences Inc [NASDAQ: IDYA] stock has seen the most recent analyst activity on July 08, 2024, when Mizuho initiated its Outperform rating and assigned the stock a price target of $50. Previously, BTIG Research started tracking the stock with Buy rating on March 08, 2024, and set its price target to $55. On August 08, 2023, SVB Securities initiated with a Outperform rating and assigned a price target of $33 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $32 on May 24, 2023. Stifel upgraded its rating to a Buy and raised its price target to $24 on April 24, 2023. Berenberg started tracking with a Buy rating for this stock on March 23, 2023, and assigned it a price target of $26. In a note dated February 28, 2023, RBC Capital Mkts initiated an Outperform rating and provided a target price of $25 on this stock.
For the past year, the stock price of Ideaya Biosciences Inc fluctuated between $23.41 and $47.74. Currently, Wall Street analysts expect the stock to reach $48.2 within the next 12 months. Ideaya Biosciences Inc [NASDAQ: IDYA] shares were valued at $30.20 at the most recent close of the market. An investor can expect a potential return of 59.6% based on the average IDYA price forecast.
Analyzing the IDYA fundamentals
According to Ideaya Biosciences Inc [NASDAQ:IDYA], the company’s sales were 11.96M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at -16.0%, Pretax Profit Margin comes in at -12.85%, and Net Profit Margin reading is -12.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.21 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.17 points at the first support level, and at 28.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.76, and for the 2nd resistance point, it is at 31.31.
Ratios To Look Out For
It is important to note that Ideaya Biosciences Inc [NASDAQ:IDYA] has a current ratio of 17.50. On the other hand, the Quick Ratio is 17.50, and the Cash Ratio is 4.49. Considering the valuation of this stock, the price to sales ratio is 213.32, the price to book ratio is 2.47.
Transactions by insiders
Recent insider trading involved Jason Throne, Former Officer, that happened on Aug 26 ’24 when 75000.0 shares were purchased. Chief Scientific Officer, WHITE MICHAEL ANTHONY completed a deal on May 29 ’24 to sell 28500.0 shares. Meanwhile, President and CEO Hata Yujiro S sold 83856.0 shares on May 15 ’24.
